| Literature DB >> 27994766 |
Iva Navratilova1, Tonia Aristotelous1, Sarah Picaud2, Apirat Chaikuad2, Stefan Knapp2, Panagis Filappakopoulos3, Andrew L Hopkins1.
Abstract
The discovery of novel bromodomain inhibitors by fragment screening is complicated by the presence of dimethyl sulfoxide (DMSO), an acetyl-lysine mimetic, that can compromise the detection of low affinity fragments. We demonstrate surface plasmon resonance as a primary fragment screening approach for the discovery of novel bromodomain scaffolds, by describing a protocol to overcome the DMSO interference issue. We describe the discovery of several novel small molecules scaffolds that inhibit the bromodomains PCAF, BRD4, and CREBBP, representing canonical members of three out of the seven subfamilies of bromodomains. High-resolution crystal structures of the complexes of key fragments binding to BRD4(1), CREBBP, and PCAF were determined to provide binding mode data to aid the development of potent and selective inhibitors of PCAF, CREBBP, and BRD4.Entities:
Keywords: BRD4; Bromodomains; CREBBP; PCAF; fragment screening; surface plasmon resonance
Year: 2016 PMID: 27994766 PMCID: PMC5150684 DOI: 10.1021/acsmedchemlett.6b00154
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345